重组组织型纤溶酶原激活药治疗急性心肌梗死

目的：观察重组组织型纤溶酶原激活药（rt-PA)治疗急性心肌梗死的疗效。方法：溶栓组15例，对照组35例，均用常规处理，溶栓组加用rt-PA治疗。结果：溶栓组在胸痛缓解时间、心肌图改变程度及时间、血清酶学变化时间均明显优于对照组，病死率明显低于对照组（P＜0．01）。结论：rt-PA用于AMI溶栓治疗可最大限度缩小梗死面积，有利于迅速改善心功能，提高生存率。

Treating acute myocardial infarct with recombinant tissue-type plasminogen activator

Objective: To Observe the effect of recombinant tissue type plasminogen activator (rt PA) in treatment of acute myocardial infarct. Methods: Two groups of patients were observed. The subjects in the control group (35 patients) were treated with routine intervention, while those in thrombolysis group (15 patients) were treated with rt PA in addition to the routine intervention. Results: There is a better outcome in the thrombolysis group as compared with that in the control group, in terms of length of angina relief, degree and length of EKG changes as well as the time for serum enzyme changes. The mortality rate in the thrombolysis group was significantly lower than that in the control group (P<0.01). Conclusion: The rt PA for thrombolysis in acute myocardial infarct patients can reduce the infarct size and improve the cardiac function rapidly as well as increase the survival rate.